Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch & Lomb

This article was originally published in The Tan Sheet

Executive Summary

Firm announces a $4.7 mil. charge to second quarter earnings to settle a consumer class action lawsuit related to B&L's marketing and labeling of contact lens care and eye care solutions. Under the settlement, B&L will change labeling and packaging to make "description of ingredients consistent with chemically identical solutions sold by B&L with different names, for other uses and at less expensive prices." The firm also will include a total of $12 mil. in coupons inside contact lens solution packaging. A fairness hearing on the settlement is slated for Sept. 13. Second quarter vision care sales for the three months ended June 24 were $258.6 mil., down 2.1% from the year-ago period

Firm announces a $4.7 mil. charge to second quarter earnings to settle a consumer class action lawsuit related to B&L's marketing and labeling of contact lens care and eye care solutions. Under the settlement, B&L will change labeling and packaging to make "description of ingredients consistent with chemically identical solutions sold by B&L with different names, for other uses and at less expensive prices." The firm also will include a total of $12 mil. in coupons inside contact lens solution packaging. A fairness hearing on the settlement is slated for Sept. 13. Second quarter vision care sales for the three months ended June 24 were $258.6 mil., down 2.1% from the year-ago period.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel